CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update.
CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.
CAMBRIDGE, Mass., April 4, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020 Inducement Plan.
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
CAMBRIDGE, Mass., Feb. 15, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023 and provided financial guidance.
With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines to Report Fourth Quarter & Full Year 2023 Financial Results
Blueprint drops lung cancer programs after seeing early data